Prelude Therapeutics (PRLD) announced a clinical trial collaboration with BeiGene (BGNE), for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, in hematologic malignancies.Inhibition of BTK is an active therapeutic approach in several B cell malignancies and the combination of CDK9 inhibition with BTK inhibition has demonstrated, in recent data publications, synergistic clinical efficacy over BTK inhibition alone; hence, there is a strong rationale for studying the combination in patients with certain hematologic malignancies. Under terms of the clinical trial collaboration agreement, BeiGene will provide zanubrutinib to Prelude, and Prelude will retain all global operational, development and commercialization rights and responsibilities for PRT2527.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRLD:
- Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
- Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
- Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences